



FAX Completed Form To 1.833.404.2392

Pharmacy Help Desk 1.800.460.8988

Prescriber Help Desk 1.833.587.2012

Request for Prior Authorization DIRECT ORAL ANTICOAGULANTS

(PLEASE PRINT - ACCURACY IS IMPORTANT)

IA Medicaid Member ID #	Patient name	DOB		
Patient address				
Provider NPI	Prescriber name	Phone		
Prescriber address		Fax		
Pharmacy name	Address	Phone		
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.				
Pharmacy NPI	Pharmacy fax	NDC 		
Prior authorization (PA) is not required for preferred direct oral anticoagulants (DOACs). Prior authorization is required for non-preferred DOACs. Requests will be considered for FDA approved dosing and length of therapy for submitted diagnosis. Requests for doses outside of the manufacturer recommended dose will not be considered. Payment will be considered for FDA approved or compendia indications for the requested drug under the following conditions: 1) Patient is within the FDA labeled age for indication; and 2) Patient does not have a mechanical heart valve; and 3) Patient does not have active bleeding; and 4) For a diagnosis of atrial fibrillation or stroke prevention, patient has the presence of at least one additional risk factor for stroke, with a CHA ₂ DS ₂ -VASc score ≥1; and 5) A recent creatinine clearance (CrCl) is provided; and 6) A recent Child-Pugh score is provided; and 7) Patient's current body weight is provided; and 8) Patient has documentation of a trial and therapy failure at a therapeutic dose with at least two preferred DOACs; and 9) For requests for edoxaban, when prescribed for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), documentation patient has had 5 to 10 days of initial therapy with a parenteral anticoagulant (low molecular weight heparin or unfractionated heparin) is provided. The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated. Preferred (no PA required if within established quantity limits) Pradaxa Patient Payman				
Diagnosis:				
Does patient have mechani	ical heart valve?	No No		
Does patient have active bl	_	_		
Patient body weight:		Date obtained:		
Provide recent creatinine clearance (CrCI):		Date obtained:		
Provide recent Child-Pugh	score:	Date completed:		







FAX Completed Form To 1.833.404.2392

Pharmacy Help Desk 1.800.460.8988

Prescriber Help Desk 1.833.587.2012

Request for Prior Authorization DIRECT ORAL ANTICOAGULANTS

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Risk factor based CHA₂DS₂-VASc Score

Requests for a diagnosis of atrial fibrillation or stroke prevention:

	RISK Factors	Score	
	Congestive heart failure	1	1
	☐ Hypertension	1	
	☐ Age ≥ 75 years	2]
	Age between 65 and 74 years	1]
	Stroke / TIA / TE	2	
	 Vascular disease (previous MI, peripheral arterial disease or aortic plaque) 	1	
	☐ Diabetes mellitus	1	
	☐ Female	1	
	Tota	al	
Document 2 preferred Do	OAC trials:		
Preferred DOAC Trial 1: N	lame/Dose: T	rial Dates:	
Failure reason:			
Preferred DOAC Trial 2: Name/Dose:		rial Dates:	
Failure reason:			
Requests for edoxaban ((Savaysa):		
	5 to 10 days of initial therapy with a parente heparin) for diagnosis of DVT or PE:	ral anticoagula	ากt (low molecular weight
Drug name & dose: T		rial dates:	
Medical or contraindication	n reason to override trial requirements:		
Attach lah rosults and or	ther documentation as necessary.		
	_	Data of sultr	
Prescriber signature (Must m	atch prescriber listed above.)	Date of subr	HISSION

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

Page 2 of 2 Rev 11/20